WO2012139099A3 - Vaccin contre le virus de l'herpès simplex - Google Patents

Vaccin contre le virus de l'herpès simplex Download PDF

Info

Publication number
WO2012139099A3
WO2012139099A3 PCT/US2012/032728 US2012032728W WO2012139099A3 WO 2012139099 A3 WO2012139099 A3 WO 2012139099A3 US 2012032728 W US2012032728 W US 2012032728W WO 2012139099 A3 WO2012139099 A3 WO 2012139099A3
Authority
WO
WIPO (PCT)
Prior art keywords
herpes simplex
simplex virus
virus vaccine
hsv
antibodies
Prior art date
Application number
PCT/US2012/032728
Other languages
English (en)
Other versions
WO2012139099A2 (fr
Inventor
Georgia D. Tomaras
Barton F. Haynes
Anthony M. Moody
Hua-Xin Liao
Jerome Kim
Nelson MICHAEL
Original Assignee
Duke University
The Government Of The United States, As Represented By The Secretary Of The Army, On Behalf Of Walter Reed Army Institute Of Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University, The Government Of The United States, As Represented By The Secretary Of The Army, On Behalf Of Walter Reed Army Institute Of Research filed Critical Duke University
Publication of WO2012139099A2 publication Critical patent/WO2012139099A2/fr
Publication of WO2012139099A3 publication Critical patent/WO2012139099A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

La présente invention porte, en général, sur le virus de l'Herpès simplex (VHS) et, en particulier, sur des anticorps qui sont spécifiques à la glycoprotéine D (gD) du VHS. L'invention porte également sur des utilisations prophylactiques et thérapeutiques de tels anticorps.
PCT/US2012/032728 2011-04-08 2012-04-09 Vaccin contre le virus de l'herpès simplex WO2012139099A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161473666P 2011-04-08 2011-04-08
US61/473,666 2011-04-08

Publications (2)

Publication Number Publication Date
WO2012139099A2 WO2012139099A2 (fr) 2012-10-11
WO2012139099A3 true WO2012139099A3 (fr) 2012-11-29

Family

ID=46969867

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/032728 WO2012139099A2 (fr) 2011-04-08 2012-04-09 Vaccin contre le virus de l'herpès simplex

Country Status (1)

Country Link
WO (1) WO2012139099A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042836A (en) * 1993-06-07 2000-03-28 Genentech, Inc. HIV envelope polypeptides
US20050025779A1 (en) * 2003-06-12 2005-02-03 Vaxgen, Inc. HIV-1 envelope glycoproteins having unusual disulfide structure
US20100330112A1 (en) * 2009-05-22 2010-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042836A (en) * 1993-06-07 2000-03-28 Genentech, Inc. HIV envelope polypeptides
US20050025779A1 (en) * 2003-06-12 2005-02-03 Vaxgen, Inc. HIV-1 envelope glycoproteins having unusual disulfide structure
US20100330112A1 (en) * 2009-05-22 2010-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE NCBI 26 March 2010 (2010-03-26), accession no. P_044668 *
DOUGLAS H. SMITH ET AL.: "Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies", PLOS ONE, vol. 5, no. 8, 2010, pages E12076 *
MICHAEL W. FERENCZY.: "Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus", CURRENT PHARMACEUTICAL DESIGN, vol. 13, no. 19, 2007, pages 1975 - 1988, XP002578572 *

Also Published As

Publication number Publication date
WO2012139099A2 (fr) 2012-10-11

Similar Documents

Publication Publication Date Title
IN2014KN02929A (fr)
PH12018500855A1 (en) Herpes simplex virus vaccine
PH12015500390B1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
PL2917229T3 (pl) Przeciwciała i ich fragmenty aktywowane przeciwko domenie alfa-3 białka HLA-G, sposoby i środki ich wytwarzania oraz ich zastosowania
MX358224B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
TN2014000438A1 (en) Anti-fcrn antibodies
WO2013106834A3 (fr) Peptides wt-1 immunogènes et leurs procédés d'utilisation
MX357965B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar.
WO2011103453A3 (fr) Vaccins destinés à être utilisés pour la prophylaxie et le traitement d'une maladie liée au virus de la grippe
WO2013054199A3 (fr) Antigènes de cmv et leurs utilisations
WO2012027365A3 (fr) Formes pharmaceutiques multi-épitopes ciblées servant à l'induction d'une réponse immunitaire dirigée contre des antigènes
IN2014DN10288A (fr)
CA2872308A1 (fr) Nouveaux agents de liaison a la ha
MX2012008790A (es) Antigenos de tuberculosis modificados.
WO2012139106A3 (fr) Virus de l'herpès simplex
WO2013006569A3 (fr) Vaccin contre le virus de l'herpès et procédés d'utilisation
EP3010340A4 (fr) Compositions et méthodes de potentialisation de la réponse immunitaire, de stimulation de l'immunothérapie et d'augmentation de la puissance d'un vaccin
WO2011079073A3 (fr) Vaccins anti-virus herpès simplex
WO2014160747A3 (fr) Compositions et méthodes de traitement ou de prévention d'une infection par le virus de l'immunodéficience humaine
WO2011098778A3 (fr) Peptides pour vaccins contre l'allergie au bouleau
EP3157554A4 (fr) Compositions, méthodes et thérapies pour l'administration de peptide antigénique
EP2928492A4 (fr) Protéines d'enveloppe du vih-1 et leurs fragments qui possèdent des épitopes reconnus par des anticorps largement neutralisants
EP2747779A4 (fr) Vaccin contre le virus de l'herpès simplex sous forme de nanoémulsion
WO2012139097A3 (fr) Procédé d'induction d'anticorps neutralisants dirigés contre le virus de l'immunodéficience humaine
WO2014172309A3 (fr) Compositions thérapeutiques pour neutraliser les interférons de type i, et procédés d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12767368

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12767368

Country of ref document: EP

Kind code of ref document: A2